Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Jun 29, 2022 2:57am
203 Views
Post# 34789580

RE:RE:RE:AGM

RE:RE:RE:AGM

Thanks CS  - good analysis and agree the FDA will likely give them the nod as to when to press the button.It could be with the next batch of 3 month data (end of August?) but more likely 6 months’. That would tie in with late 22/23. Was concerned that this critical milestone went unmentioned in the ann of the 21st having been serially referred to prior - so many timelines have evaporated here in the past. Detailed feedback from the AGM may provide re-assurance.

 

The anti-viral vaccine could be a big deal in itself if also on track. Live preclinical Trials were scheduled to commence in Q2. Have or will they? Hopefully this was likewise confirmed at the Meeting.

 
<< Previous
Bullboard Posts
Next >>